INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Jan 09, 2006 |
Director, EVP, CSO, & Pres Regn Res Labs
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Open market or private sale of non-derivative or derivative security | 74 | $16.99 | 66,642 |
| Jan 09, 2006 |
Director, EVP, CSO, & Pres Regn Res Labs
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Open market or private sale of non-derivative or derivative security | 74 | $17.02 | 66,517 |
| Mar 10, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 60 | $480.34 | 520,299 |
| May 15, 2024 |
Director, Bd. Co-Chair, President & CSO
|
Director, Bd. Co-Chair, President & CSO | Form 4 | Open market or private sale of non-derivative or derivative security | 53 | $984.02 | 838,147 |
| Jan 09, 2004 |
Director, EVP, CSO, & Pres Regn Res Labs
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Open market or private sale of non-derivative or derivative security | 51 | $15.66 | 64,766 |
| Jan 09, 2004 |
Director, EVP, CSO, & Pres Regn Res Labs
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Open market or private sale of non-derivative or derivative security | 51 | $15.57 | 64,698 |
| Jan 09, 2004 |
Director, EVP, CSO, & Pres Regn Res Labs
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Open market or private sale of non-derivative or derivative security | 51 | $15.35 | 64,596 |
| Jan 09, 2004 |
Director, EVP, CSO, & Pres Regn Res Labs
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Open market or private sale of non-derivative or derivative security | 50 | $15.33 | 63,478 |
| Mar 23, 2023 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 47 | $805.55 | 197,948 |
| Dec 17, 2012 |
Director, EVP CSO Pres Regen Res Labs
|
Director, EVP CSO Pres Regen Res Labs | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 47 | $179.13 | 1,294,708 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.